Skip to main content
Signal8
Launch Terminal

SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Biotechnology

SpyGlass Pharma, Inc. Common Stock logo

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGPHealthcare
-0.83%$32.24
AH$32.24+0.00%vs close
Mkt Cap$1.08B
Float5.94M
O/S33.45M
Vol
$ Vol
RVOL
Inst Own78.1%
SI20.6%
Earnings
Dilution
SpyGlass Pharma, Inc. Common Stock logoNASDAQ:SGP$32.24-0.83%
Phase Distribution
6 lead-sponsored trials·4 active·1 completed
Phase 11
Phase 1/21
Phase 32
Not applicable2
Status Overview
Not yet recruiting1
Recruiting2
Active, not recruiting2
Completed1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Recruiting

    Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

    Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%

    Cataract, Glaucoma +1

    Enrollment
    400
    Start
    Oct 2025
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2031est.
    NCT07218783
  • Phase 3
    Recruiting

    Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

    Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%

    Cataract, Glaucoma +1

    Enrollment
    400
    Start
    Oct 2025est.
    Primary Completion
    May 2029est.
    Completion
    May 2031est.
    NCT07218796
  • Phase 1/2
    Active, not recruiting

    Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

    Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose)

    Cataract, Glaucoma +1

    Enrollment
    201
    Start
    Oct 2023
    Primary Completion
    Jan 2025
    Completion
    Nov 2027est.
    NCT06120842
  • Phase 1
    Not yet recruiting

    Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension

    BIM-DRS Low Dose, BIM-DRS High Dose

    Glaucoma, Ocular Hypertension

    Enrollment
    24
    Start
    Jul 2026est.
    Primary Completion
    Feb 2027est.
    Completion
    Mar 2030est.
    NCT07641296
  • Not applicable
    Completed

    Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma

    Bimatoprost Implant System / IOL Combination

    Cataract, Ocular Hypertension +1

    Enrollment
    24
    Start
    Apr 2022
    Primary Completion
    Dec 2022
    Completion
    Dec 2022
    NCT07154797
  • Observational
    Active, not recruiting

    Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination

    -

    Glaucoma, Cataract +1

    Enrollment
    23
    Start
    Mar 2023
    Primary Completion
    Apr 2031est.
    Completion
    Apr 2031est.
    NCT07154810
Search ClinicalTrials.gov for “SpyGlass Pharma”